Randomized, Double-blind Crossover Trial Comparing Low-GI Functional vs. Standard Wholegrain Carbohydrates on Glycolipid Metabolism and Vascular Stress Markers in Adults With Suboptimal Triglyceridemia

NCT ID: NCT07198789

Last Updated: 2025-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-30

Study Completion Date

2026-05-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Low-glycemic index (GI) carbohydrates help prevent type 2 diabetes and cardiovascular disease by reducing postprandial glucose, insulin spikes, inflammation, and triglyceride synthesis. They improve weight, lipid profiles, and vascular health. Our study will compare functional low-GI vs. standard wholegrain carbs in a Mediterranean diet to assess their effect on the Triglycerides-Glucose Index, a marker of metabolic and cardiovascular risk, in subjects with suboptimal triglyceride levels.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The consumption of carbohydrates with a low glycemic index (GI) has emerged as a cornerstone in the dietary prevention of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). The glycemic index classifies carbohydrate-containing foods based on their impact on postprandial blood glucose: low-GI foods have a GI ≤ 55, medium-GI between 56 and 69, and high-GI ≥ 70. Low-GI foods cause slower and smaller rises in blood glucose and insulin, which can reduce glycemic variability and postprandial hyperglycemia.

Postprandial hyperglycemia is known to trigger oxidative stress and endothelial dysfunction, mechanisms closely involved in the pathogenesis of atherosclerosis and diabetic vascular complications. Clinical trials show that replacing high-GI carbohydrates with low-GI options improves fasting blood glucose by an average of 0.4 mmol/L and HbA1c by 0.3% in individuals with impaired glucose tolerance. These modest changes translate into meaningful reductions in the long-term risk of diabetes.

A pooled analysis of 24 prospective cohort studies found that a high-GI diet was associated with a 27% greater risk of developing T2DM. Moreover, each 5-unit increment in dietary GI increases the risk of coronary heart disease (CHD) by 13%. The metabolic advantage of low-GI carbohydrates lies in their ability to limit insulin spikes, reduce inflammatory cytokine release, and lower triglyceride synthesis.

In overweight individuals, low-GI diets are associated with greater weight loss and fat mass reduction than high-GI diets, even when total calories are similar. One study found that participants on a low-GI diet lost 1.5 kg more fat mass over 12 weeks compared to those on a high-GI diet, despite identical energy intake.

Low-GI foods also improve lipid profiles. A systematic review and meta-analysis reported a mean reduction of 0.13 mmol/L in LDL cholesterol and a 0.05 mmol/L increase in HDL cholesterol among participants consuming low-GI diets. These effects are particularly relevant in patients with metabolic syndrome or insulin resistance.

In children and adolescents, low-GI intake improves insulin sensitivity and reduces early markers of vascular damage. A randomized controlled trial demonstrated that adolescents on a low-GI diet exhibited lower carotid intima-media thickness (IMT), a surrogate marker of atherosclerosis progression, after six months.

Furthermore, a Mediterranean dietary pattern, which is naturally low in GI due to its emphasis on legumes, whole grains, and vegetables, has been linked to a 30% reduction in major cardiovascular events in high-risk populations. The PREDIMED trial showed that such a diet significantly reduced the incidence of myocardial infarction and stroke over five years.

Inflammation plays a central role in both T2DM and CVD, and low-GI diets help reduce C-reactive protein (CRP) levels by 0.5-1.0 mg/L on average. This anti-inflammatory effect may be one of the mechanisms through which low-GI diets offer cardiovascular protection.

Even among elderly individuals, adherence to low-GI diets has been associated with better cognitive function and glycemic control. A cross-sectional analysis showed that older adults in the highest tertile of dietary GI had significantly lower memory scores than those in the lowest tertile.

The combined effects of low-GI diets-improving glucose control, reducing inflammation, enhancing lipid profiles, and promoting satiety-make them an essential component of preventive nutrition strategies for chronic disease.

Public health guidelines increasingly recommend the substitution of refined carbohydrates with low-GI alternatives to curb the global diabetes epidemic. However, no direct comparison has been made so far between functional low-glycemic index carbohydrates and standard wholegrain carbohydrates in the context of a Mediterranean diet.

In this context, the primary purpose of our research will be to evaluate if functional low-glycemic index carbohydrates are able to reduce the Triglycerides-Glucose Index plasma levels versus standard wholegrain carbohydrates in healthy subjects with suboptimal triglycerides levels. The Triglycerides-Glucose Index is a cheap, validated, emerging risk factors for both metabolic and cardiovascular diseases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Prevention Diabetes Prevention Inflammation Nutrition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Altograno® Bakery Foods

Altograno® Pasta, Pizza and Flatbrad

Group Type ACTIVE_COMPARATOR

Altograno® Bakery Foods

Intervention Type OTHER

Altograno® Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet

Standard Whole-Grain Bakery Foods

Industrial standard whole-grain Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet

Group Type PLACEBO_COMPARATOR

Standard Whole-Grain Bakery Foods

Intervention Type OTHER

Industrial standard whole-grain Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Altograno® Bakery Foods

Altograno® Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet

Intervention Type OTHER

Standard Whole-Grain Bakery Foods

Industrial standard whole-grain Pasta, Pizza and Flatbrad, in substitution of the same amount of carbohydrates usually eaten in a stabilized diet

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged ≥ 18 years
* TG\>150 mg/dL
* Subjects who have the capability to communicate and to comply with the study's requirements.
* Subjects agree to participate in the study and having dated and signed the informed consent form.

Exclusion Criteria

* Gluten hypersensitivity/Coeliac disease diagnosis
* BMI\>30 kg/m2
* Any preventive treatments (i.e. lipid-lowering drugs, antihypertensives) not stabilized in type and dose for at least 3 months
* Any medical or surgical condition that would limit the patient adhesion to the study protocol.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Bologna

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Arrigo F.G. Cicero

MD, PhD

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PNRR_ONFOODS_LowCharb

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.